Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$2.30 – $15.15
67% from low
Borrow rate
1.84%
Moderate
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $73.1M | $226.2M | $659.7M | $1.19B | $1.22B | $1.37B | $1.28B | $1.29B |
| Cost of revenue | $36.6M | $213.7M | $548.2M | $705.0M | $732.3M | $884.9M | $833.3M | $792.1M |
| Gross profit | $36.5M | $12.5M | $111.6M | $480.4M | $492.6M | $486.4M | $445.0M | $498.2M |
| Gross margin | 49.9% | 5.5% | 16.9% | 40.5% | 40.2% | 35.5% | 34.8% | 38.6% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$27.5M | −$128.4M | −$160.2M | $58.1M | $62.4M | $43.7M | $19.2M | $25.9M |
| EBITDA | −$38.2M | $16.5M | $189.0M | $148.6M | $161.3M | $191.4M | $221.9M | $166.9M |
| Net income | −$53.6M | −$68.8M | −$60.2M | −$204.1M | −$355.4M | −$286.4M | −$226.7M | −$235.1M |
| Net margin | -73.3% | -30.4% | -9.1% | -17.2% | -29.0% | -20.9% | -17.7% | -18.2% |
| EPS (diluted) | -0.48 | -0.45 | -0.33 | -0.48 | -1.59 | -1.20 | -0.87 | -0.93 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.3B | $-0.09 | $-0.13–$-0.02 | 3 |
| 2027 | $1.4B | $-0.17 | $-0.24–$-0.09 | 3 |
| 2028 | $1.6B | $-0.03 | $-0.03–$-0.03 | 1 |
| 2029 | $1.7B | $0.05 | $0.05–$0.05 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds CURLF.
No tracked institution reports a position in CURLF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2026-06-05 | 1-for-3reverse |
No one on the platform has traded CURLF yet.
| $2.6B |
| — |
| HMDCFHUTCHMED (China) Limited | $2.16 | +0.00% | $1.9B | — |
| HTSUFHisamitsu Pharmaceutical Co., Inc. | $29.00 | +0.00% | $2.0B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 2.1× sales vs its 2.2× historical median P/S.
Fair value ≈ $11.86 · price $10.92 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.